Supported by these hypotheses and evidence, it has been recently described the outcomes of human-recombinant nerve growth factor (hr-NGF) treatment in an infant six months after a group B Streptococcus (GBS) meningitis [31]. This evidence concerns the gene NGF and infectious meningitis.